Copyright
©The Author(s) 2021.
World J Gastroenterol. Feb 14, 2021; 27(6): 501-512
Published online Feb 14, 2021. doi: 10.3748/wjg.v27.i6.501
Published online Feb 14, 2021. doi: 10.3748/wjg.v27.i6.501
Table 6 Comparison of serum carbohydrate antigen 125 levels in mucinous cystic neoplasms and intraductal papillary mucinous neoplasms
| Overall | Benign | Advanced | |
| mean ± SD (U/mL) (IPMN) | 14.6 ± 12.2 | 12.7 ± 7.56 | 17.3 ± 16.4 |
| mean ± SD (U/mL) (MCN) | 30.5 ± 40.5 | 14.3 ± 6.4 | 74.4 ± 60.3 |
| Comparison P value | 0.001 | 0.69 | < 0.0001 |
| ≥ 35/< 35 U/mL (IPMN) | 5/104 | 1/63 | 4/41 |
| ≥ 35/< 35 U/mL (MCN) | 5/21 | 0/19 | 5/2 |
| Comparison P value | 0.03 | 1.00 | < 0.0001 |
- Citation: Sun LQ, Peng LS, Guo JF, Jiang F, Cui F, Huang HJ, Jin ZD. Validation of serum tumor biomarkers in predicting advanced cystic mucinous neoplasm of the pancreas. World J Gastroenterol 2021; 27(6): 501-512
- URL: https://www.wjgnet.com/1007-9327/full/v27/i6/501.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i6.501